|
Market Closed -
Toronto S.E.
13:07:18 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 0.0200 CAD | 0.00% |
|
0.00% | -42.86% |
| 05-30 | Quest PharmaTech Inc. Reports Earnings Results for the Full Year Ended January 31, 2026 | CI |
| 05-29 | Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt | CI |
Company Valuation: Quest PharmaTech Inc.
Data adjusted to current consolidation scope
| Fiscal Period: January | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 32.76 | 15.14 | 11.84 | 4.228 | 5.92 | 5.92 |
| Change | - | -53.78% | -21.81% | -64.29% | 40% | 0% |
| Enterprise Value (EV) 1 | 32.87 | 15.39 | 12.46 | 4.511 | 6.714 | 6.905 |
| Change | - | -53.17% | -19.02% | -63.81% | 48.84% | 2.84% |
| P/E | 0.18x | -0.18x | -1.61x | -1.4x | -3.29x | 1.18x |
| PBR | 0.19x | 0.17x | 0.14x | 0.18x | 0.28x | 0.22x |
| PEG | - | 0x | 0x | 0x | 0.1x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -30.8x | -19.5x | -15.2x | -3.44x | -8.25x | - |
| EV / EBIT | -30.7x | -19.5x | -14.9x | -3.43x | -8.22x | -9.71x |
| EV / FCF | -1.83x | -138x | -21x | -279x | -13.5x | -32.1x |
| FCF Yield | -54.6% | -0.72% | -4.76% | -0.36% | -7.4% | -3.12% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 1.112 | -0.5055 | -0.0435 | -0.0178 | -0.0106 | 0.0296 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -1.068 | -0.7887 | -0.8207 | -1.313 | -0.8143 | - |
| EBIT 1 | -1.07 | -0.7906 | -0.8342 | -1.316 | -0.8173 | -0.7113 |
| Net income 1 | 190.1 | -85.04 | -7.332 | -3.018 | -1.801 | 4.998 |
| Net Debt 1 | 0.1053 | 0.2497 | 0.6253 | 0.283 | 0.7949 | 0.9856 |
| Reference price 2 | 0.1950 | 0.0900 | 0.0700 | 0.0250 | 0.0350 | 0.0350 |
| Nbr of stocks (in thousands) | 167,999 | 168,239 | 169,129 | 169,129 | 169,129 | 169,129 |
| Announcement Date | 5/31/21 | 5/26/22 | 5/31/23 | 5/29/24 | 5/28/25 | 5/30/26 |
1CAD in Million2CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 2.46M | |
| 34.78x | 6.2x | 18.42x | 0.92% | 51.61B | |
| -21.47x | 297.59x | -22.09x | -.--% | 44.89B | |
| 33.46x | 3.25x | 14.02x | -.--% | 42.77B | |
| 49.05x | 5.7x | 31.17x | -.--% | 42.58B | |
| 29.21x | 8.45x | 21.35x | 0.39% | 31.82B | |
| 35.3x | 5.79x | 26.33x | -.--% | 17.33B | |
| 24.28x | 2.11x | 9.13x | 1.11% | 14.76B | |
| 78.97x | 4.14x | 16.07x | -.--% | 14.09B | |
| Average | 32.95x | 41.65x | 14.30x | 0.3% | 28.87B | |
| Weighted average by Cap. | 28.33x | 55.88x | 13.02x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- QPT Stock
- Valuation Quest PharmaTech Inc.
Select your edition
All financial news and data tailored to specific country editions
